A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.

Valerie LeungSuzanne GillAndrea LlanesArmughan KhawajaAmanda StaggJanine McCreadyMariana JacubovichGrace HoJeff PowisChristopher Kandel

Published in: PloS one (2023)

Nirmatrelvir-ritonavir was associated with a high prevalence of clinically significant DDIs, which required mitigation strategies and a high frequency of mild ADEs. Collaborative assessment to address medication alterations resulted in high treatment adherence.

Keyphrases

high frequency
transcranial magnetic stimulation
primary care
healthcare
coronavirus disease
sars cov
climate change
antiretroviral therapy
mental health
adverse drug
quality improvement
emergency department
type diabetes
metabolic syndrome
combination therapy
insulin resistance
adipose tissue
replacement therapy